Opinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?

Writing from cancer care, the author describes a persistent contradiction: patients ask how to manage pain, fatigue, anxiety, immune suppression, and the daily toll of the disease, but clinicians often prescribe only medication even though they know other evidence-based treatments could help. Those include acupuncture for chemotherapy-induced nausea, exercise and nutrition counseling to improve clinical outcomes, and mindfulness-based programs to ease distress, sleep problems, and even immune dysfunction. When doctors and patients do discuss these options, the conversation too often ends with “Insurance doesn’t cover that,” a disconnect the author calls indefensible.

Over the past two decades, the field of integrative oncology—the evidence-informed use of mind-body practices, lifestyle interventions, and selected complementary therapies alongside conventional cancer treatment—has moved from a fringe idea to a mature clinical discipline. It now has clinical practice guidelines jointly developed by the Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO), and recommendations embedded throughout National Comprehensive Cancer Network (NCCN) guidelines. The author argues that when ASCO and NCCN agree a treatment is effective and safe, that should carry decisive weight in coverage decisions—yet coverage remains inconsistent, fragmented, and inequitable. This is no longer primarily a scientific problem, the piece says, but a policy failure.

Integrative oncology earned legitimacy by embracing science and evidence-based medicine, the author writes: leaders demanded better research, standardized methods, and clinical trials to confirm safety and efficacy; the field studied what patients were already using, rigorously tested what worked, and built guidelines grounded in evidence rather than ideology. That approach paid off. Randomized clinical trials and meta-analyses now show that specific integrative interventions meaningfully reduce cancer-related pain, fatigue, anxiety, depression, sleep disturbance, neuropathy, hot flashes, and treatment-related nausea. Many of these outcomes are not subjective. These therapies can influence immune function, inflammation, stress hormones, and patients’ ability to tolerate and complete lifesaving therapies, and better symptom control often means patients stay on treatment longer and recover better. This evidence base is why ASCO endorses integrative oncology guidelines and why NCCN incorporates integrative therapies throughout symptom-management pathways: acupuncture is recommended for pain and nausea, mindfulness-based interventions are recommended for anxiety, depression, and fatigue, and exercise and nutrition counseling are no longer optional extras but foundational components of comprehensive cancer care.

The author’s core implication is that patients are now told these interventions work, then asked to pay for them out of pocket. The excerpt turns toward access in the United States before cutting off mid-sentence, leaving the central policy question—why insurers do not consistently pay for guideline-supported integrative cancer care—as the piece’s main challenge.